IART

SEC source: 0001209191-17-012104 · doc4.xml · nonDerivative · entry 2

Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,461

F3 · shares: On February 15, 2017, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2016, at least a 3% increase in annual revenue over the prior fiscal year, under the March 23, 2015 Performance Stock Award. Accordingly, 33% of the shares will vest on March 23, 2017, the second anniversary of the grant date.

SEC source: 0001209191-17-012104 · doc4.xml · nonDerivative · entry 1

Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,543

F1 · shares: On February 15, 2017, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2016, at least a 3% increase in annual revenue over the prior fiscal year, under the March 24, 2014 Performance Stock Award. Accordingly, 34% of the shares will vest on March 24, 2017, the third anniversary of the grant date.

F2 · balance_after: On December 21, 2016, the common stock of Integra LifeSciences Holdings Corporation split two-for-one, resulting in the reporting person's ownership of one additional share of common stock for each share of common stock owned as of that date and one additional unit of unvested performance based restricted stock ("PSU") for each PSU owned as of that date, as reflected in the totals listed on this Form 4.

SEC source: 0001209191-17-012143 · doc4.xml · nonDerivative · entry 3

OGRADY JUDITH · CIK 0001187573 · CorpVP,Global Reg.Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,870

F4 · shares: On February 15, 2017, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2016, at least 3% and up to a maximum of 11% increase in annual revenue over the prior fiscal year, under the March 14, 2016 Performance Stock Award. Accordingly, 33% of the shares will vest on March 14, 2017 at 150% target, the first anniversary of the grant date.

SEC source: 0001209191-17-012143 · doc4.xml · nonDerivative · entry 2

OGRADY JUDITH · CIK 0001187573 · CorpVP,Global Reg.Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,096

F3 · shares: On February 15, 2017, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2016, at least a 3% increase in annual revenue over the prior fiscal year, under the March 23, 2015 Performance Stock Award. Accordingly, 33% of the shares will vest on March 23, 2017, the second anniversary of the grant date.

SEC source: 0001209191-17-012143 · doc4.xml · nonDerivative · entry 1

OGRADY JUDITH · CIK 0001187573 · CorpVP,Global Reg.Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,486

F1 · shares: On February 15, 2017, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2016, at least a 3% increase in annual revenue over the prior fiscal year, under the March 24, 2014 Performance Stock Award. Accordingly, 34% of the shares will vest on March 24, 2017, the third anniversary of the grant date.

F2 · balance_after: On December 21, 2016, the common stock of Integra LifeSciences Holdings Corporation split two-for-one, resulting in the reporting person's ownership of one additional share of common stock for each share of common stock owned as of that date and one additional unit of unvested performance based restricted stock ("PSU") for each PSU owned as of that date, as reflected in the totals listed on this Form 4.

SEC source: 0001209191-17-012186 · doc4.xml · nonDerivative · entry 3

VINHAIS JOSEPH · CIK 0001563599 · Corp VP,Global Qlty Assurance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,586

F4 · shares: On February 15, 2017, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2016, at least 3% and up to a maximum of 11% increase in annual revenue over the prior fiscal year, under the March 14, 2016 Performance Stock Award. Accordingly, 33% of the shares will vest on March 14, 2017 at 150% target, the first anniversary of the grant date.

SEC source: 0001209191-17-012186 · doc4.xml · nonDerivative · entry 2

VINHAIS JOSEPH · CIK 0001563599 · Corp VP,Global Qlty Assurance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,644

F3 · shares: On February 15, 2017, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2016, at least a 3% increase in annual revenue over the prior fiscal year, under the March 23, 2015 Performance Stock Award. Accordingly, 33% of the shares will vest on March 23, 2017, the second anniversary of the grant date.

SEC source: 0001209191-17-012186 · doc4.xml · nonDerivative · entry 1

VINHAIS JOSEPH · CIK 0001563599 · Corp VP,Global Qlty Assurance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,032

F1 · shares: On February 15, 2017, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2016, at least a 3% increase in annual revenue over the prior fiscal year, under the March 24, 2014 Performance Stock Award. Accordingly, 34% of the shares will vest on March 24, 2017, the third anniversary of the grant date.

F2 · balance_after: On December 21, 2016, the common stock of Integra LifeSciences Holdings Corporation split two-for-one, resulting in the reporting person's ownership of one additional share of common stock for each share of common stock owned as of that date and one additional unit of unvested performance based restricted stock ("PSU") for each PSU owned as of that date, as reflected in the totals listed on this Form 4.

SEC source: 0001209191-17-012173 · doc4.xml · nonDerivative · entry 3

MOORADIAN JOHN · CIK 0001563593 · Corp VP, Global Ops & Supp Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,348

F4 · shares: On February 15, 2017, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2016, at least 3% and up to a maximum of 11% increase in annual revenue over the prior fiscal year, under the March 14, 2016 Performance Stock Award. Accordingly, 33% of the shares will vest on March 14, 2017 at 150% target, the first anniversary of the grant date.

SEC source: 0001209191-17-012173 · doc4.xml · nonDerivative · entry 2

MOORADIAN JOHN · CIK 0001563593 · Corp VP, Global Ops & Supp Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,058

F3 · shares: On February 15, 2017, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2016, at least a 3% increase in annual revenue over the prior fiscal year, under the March 23, 2015 Performance Stock Award. Accordingly, 33% of the shares will vest on March 23, 2017, the second anniversary of the grant date.

SEC source: 0001209191-17-012173 · doc4.xml · nonDerivative · entry 1

MOORADIAN JOHN · CIK 0001563593 · Corp VP, Global Ops & Supp Chn

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,160

F1 · shares: On February 15, 2017, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2016, at least a 3% increase in annual revenue over the prior fiscal year, under the March 24, 2014 Performance Stock Award. Accordingly, 34% of the shares will vest on March 24, 2017, the third anniversary of the grant date.

F2 · balance_after: On December 21, 2016, the common stock of Integra LifeSciences Holdings Corporation split two-for-one, resulting in the reporting person's ownership of one additional share of common stock for each share of common stock owned as of that date and one additional unit of unvested performance based restricted stock ("PSU") for each PSU owned as of that date, as reflected in the totals listed on this Form 4.

SEC source: 0001209191-17-012155 · doc4.xml · nonDerivative · entry 3

REUVERS DANIEL L. · CIK 0001563602 · CVP,PRES-SPC SURGICAL SOLUTION

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,617

F4 · shares: On February 15, 2017, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2016, at least 3% and up to a maximum of 11% increase in annual revenue over the prior fiscal year, under the March 14, 2016 Performance Stock Award. Accordingly, 33% of the shares will vest on March 14, 2017 at 150% target, the first anniversary of the grant date.

SEC source: 0001209191-17-012155 · doc4.xml · nonDerivative · entry 2

REUVERS DANIEL L. · CIK 0001563602 · CVP,PRES-SPC SURGICAL SOLUTION

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,168

F3 · shares: On February 15, 2017, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2016, at least a 3% increase in annual revenue over the prior fiscal year, under the March 23, 2015 Performance Stock Award. Accordingly, 33% of the shares will vest on March 23, 2017, the second anniversary of the grant date.

SEC source: 0001209191-17-012155 · doc4.xml · nonDerivative · entry 1

REUVERS DANIEL L. · CIK 0001563602 · CVP,PRES-SPC SURGICAL SOLUTION

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,222

F1 · shares: On February 15, 2017, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2016, at least a 3% increase in annual revenue over the prior fiscal year, under the March 24, 2014 Performance Stock Award. Accordingly, 34% of the shares will vest on March 24, 2017, the third anniversary of the grant date.

F2 · balance_after: On December 21, 2016, the common stock of Integra LifeSciences Holdings Corporation split two-for-one, resulting in the reporting person's ownership of one additional share of common stock for each share of common stock owned as of that date and one additional unit of unvested performance based restricted stock ("PSU") for each PSU owned as of that date, as reflected in the totals listed on this Form 4.

SEC source: 0001209191-17-012118 · doc4.xml · nonDerivative · entry 1

Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,256

F1 · shares: On February 15, 2017, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2016, at least 3% and up to a maximum of 11% increase in annual revenue over the prior fiscal year, under the March 14, 2016 Performance Stock Award. Accordingly, 33% of the shares will vest on March 14, 2017 at 150% target, the first anniversary of the grant date.

F2 · balance_after: On December 21, 2016, the common stock of Integra LifeSciences Holdings Corporation split two-for-one, resulting in the reporting person's ownership of one additional share of common stock for each share of common stock owned as of that date and one additional unit of unvested performance based restricted stock ("PSU") for each PSU owned as of that date, as reflected in the totals listed on this Form 4.

SEC source: 0001209191-17-012123 · doc4.xml · nonDerivative · entry 3

GORELICK RICHARD D. · CIK 0001563554 · Corp VP, Gen Counsel & Sec

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,306

F4 · shares: On February 15, 2017, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2016, at least 3% and up to a maximum of 11% increase in annual revenue over the prior fiscal year, under the March 14, 2016 Performance Stock Award. Accordingly, 33% of the shares will vest on March 14, 2017 at 150% target, the first anniversary of the grant date.

SEC source: 0001209191-17-012123 · doc4.xml · nonDerivative · entry 2

GORELICK RICHARD D. · CIK 0001563554 · Corp VP, Gen Counsel & Sec

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,302

F3 · shares: On February 15, 2017, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2016, at least a 3% increase in annual revenue over the prior fiscal year, under the March 23, 2015 Performance Stock Award. Accordingly, 33% of the shares will vest on March 23, 2017, the second anniversary of the grant date.

SEC source: 0001209191-17-012123 · doc4.xml · nonDerivative · entry 1

GORELICK RICHARD D. · CIK 0001563554 · Corp VP, Gen Counsel & Sec

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,290

F1 · shares: On February 15, 2017, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2016, at least a 3% increase in annual revenue over the prior fiscal year, under the March 24, 2014 Performance Stock Award. Accordingly, 34% of the shares will vest on March 24, 2017, the third anniversary of the grant date.

F2 · balance_after: On December 21, 2016, the common stock of Integra LifeSciences Holdings Corporation split two-for-one, resulting in the reporting person's ownership of one additional share of common stock for each share of common stock owned as of that date and one additional unit of unvested performance based restricted stock ("PSU") for each PSU owned as of that date, as reflected in the totals listed on this Form 4.

SEC source: 0001209191-17-012111 · doc4.xml · nonDerivative · entry 3

DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,937

F4 · shares: On February 15, 2017, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2016, at least 3% and up to a maximum of 11% increase in annual revenue over the prior fiscal year, under the March 14, 2016 Performance Stock Award. Accordingly, 33% of the shares will vest on March 14, 2017 at 150% target, the first anniversary of the grant date.

SEC source: 0001209191-17-012111 · doc4.xml · nonDerivative · entry 2

DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,292

F3 · shares: On February 15, 2017, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2016, at least a 3% increase in annual revenue over the prior fiscal year, under the March 23, 2015 Performance Stock Award. Accordingly, 33% of the shares will vest on March 23, 2017, the second anniversary of the grant date.

SEC source: 0001209191-17-012111 · doc4.xml · nonDerivative · entry 1

DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,690

F1 · shares: On February 15, 2017, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2016, at least a 3% increase in annual revenue over the prior fiscal year, under the March 24, 2014 Performance Stock Award. Accordingly, 34% of the shares will vest on March 24, 2017, the third anniversary of the grant date.

F2 · balance_after: On December 21, 2016, the common stock of Integra LifeSciences Holdings Corporation split two-for-one, resulting in the reporting person's ownership of one additional share of common stock for each share of common stock owned as of that date and one additional unit of unvested performance based restricted stock ("PSU") for each PSU owned as of that date, as reflected in the totals listed on this Form 4.

SEC source: 0001209191-17-012108 · doc4.xml · nonDerivative · entry 2

Burhop Kenneth · CIK 0001601582 · CORPVP,CHIEFSCIENTIFIC OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,048

F3 · shares: On February 15, 2017, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2016, at least 3% and up to a maximum of 11% increase in annual revenue over the prior fiscal year, under the March 14, 2016 Performance Stock Award. Accordingly, 33% of the shares will vest on March 14, 2017 at 150% target, the first anniversary of the grant date.

SEC source: 0001209191-17-012108 · doc4.xml · nonDerivative · entry 1

Burhop Kenneth · CIK 0001601582 · CORPVP,CHIEFSCIENTIFIC OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,758

F1 · shares: On February 15, 2017, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2016, at least a 3% increase in annual revenue over the prior fiscal year, under the March 23, 2015 Performance Stock Award. Accordingly, 33% of the shares will vest on March 23, 2017, the second anniversary of the grant date.

F2 · balance_after: On December 21, 2016, the common stock of Integra LifeSciences Holdings Corporation split two-for-one, resulting in the reporting person's ownership of one additional share of common stock for each share of common stock owned as of that date and one additional unit of unvested performance based restricted stock ("PSU") for each PSU owned as of that date, as reflected in the totals listed on this Form 4.

SEC source: 0001209191-17-007554 · doc4.xml · nonDerivative · entry 1

Evoli Lisa · CIK 0001661715 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,086

F1 · balance_after: On December 21, 2016, the common stock of Integra LifeSciences Holdings Corporation split two-for-one, resulting in the reporting person's ownership of one additional share of common stock for each share of common stock owned as of that date, as reflected in the totals listed on this Form 4.

SEC source: 0001209191-16-153329 · doc4.xml · derivative · entry 1

REUVERS DANIEL L. · CIK 0001563602 · CVP,PRES-SPC SURGICAL SOLUTION

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,223

Underlying: Common Stock · 5,223 shares

Expires 2024-12-01

F1 · derivative.exercise_date: 100% of the shares of stock options will vest on the third anniversary of the grant date of 12/01/2016.

SEC source: 0001209191-16-153322 · doc4.xml · derivative · entry 1

Coleman Glenn · CIK 0001434369 · CVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,187

Underlying: Common Stock · 12,187 shares

Expires 2024-12-01

F1 · derivative.exercise_date: 100% of the shares of stock options will vest on the third anniversary of the grant date of 12/01/2016.

SEC source: 0001209191-16-153325 · doc4.xml · derivative · entry 1

DAVIS ROBERT T. JR. · CIK 0001563606 · CVP,PRES-ORTHO & TISSUE TECH

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,705

Underlying: Common Stock · 8,705 shares

Expires 2024-12-01

F1 · derivative.exercise_date: 100% of the shares of stock options will vest on the third anniversary of the grant date of 12/01/2016.

SEC source: 0001209191-16-153338 · doc4.xml · nonDerivative · entry 1

HOWELL LLOYD JR · CIK 0001505488 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,048

SEC source: 0001209191-16-152451 · doc4.xml · nonDerivative · entry 1

GORELICK RICHARD D. · CIK 0001563554 · Corp VP, Gen Counsel & Sec

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,582

SEC source: 0001209191-16-152178 · doc4.xml · nonDerivative · entry 1

BRADLEY KEITH · CIK 0001188650 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,508

SEC source: 0001209191-16-149054 · doc4.xml · derivative · entry 4

Arduini Peter J · CIK 0001323134 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 175,794

Underlying: Common Stock · 20,000 shares

Expires 2020-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: One-third of the stock options vested on the first anniversary of the grant date which is March 1, 2012 and thereafter with respect to the remaining two-thirds which vested in monthly installments through the 3rd anniversary of the grant date.

SEC source: 0001209191-16-149054 · doc4.xml · nonDerivative · entry 3

Arduini Peter J · CIK 0001323134 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,593

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

F3 · price: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $80.00 to $80.11.

SEC source: 0001209191-16-149054 · doc4.xml · nonDerivative · entry 2

Arduini Peter J · CIK 0001323134 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,593

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

SEC source: 0001209191-16-149054 · doc4.xml · nonDerivative · entry 1

Arduini Peter J · CIK 0001323134 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,593

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

F2 · price: The price shown above represents the weighted average price of the shares sold. The range of sale prices was $77.00 to $77.02.

SEC source: 0001209191-16-145558 · doc4.xml · nonDerivative · entry 1

Augusti Mark A · CIK 0001481783 · CVP,PRES-ORTHO & TISSUE TECH

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,962